25-Hydroxycholecalciferol Inhibits Cell Growth and Induces Apoptosis in SiHa Cervical Cells via Autocrine Vitamin D Metabolism

Preclinical studies show that the anticancer actions of vitamin D metabolites are mediated by apoptosis, inhibition of cell proliferation and induction of cell cycle arrest. Cervical cancer cells express an autocrine vitamin D metabolising system (VDMS) comprised of a vitamin D receptor, vitamin D catabolic enzyme (CYP24A1), and the activating enzyme of 25-hydroxycholecalciferol (25(OH)D3), CYP27B1. We assessed the anticancer effects of 25(OH)D3 at clinically relevant concentrations on a cervical squamous cell cancer cell line, SiHa. We evaluated cell health parameters (cell count, viability, and cell cycle), cell death modes (apoptosis, autophagic-dependent death, and necrosis by flow cytometry and transmission electron microscopy), and autocrine VDMS gene and protein expression by qPCR and Western blot, respectively. Our study demonstrates that physiological and supraphysiological doses of 25(OH)D3 inhibit cell growth and viability and induce biochemical and morphological apoptosis in SiHa cells. These growth effects are mediated by alteration in the VDMS gene and protein expression, with prominent negative feedback at supraphysiological treatment dose. These data identify promising therapeutic potential of 25(OH)D3 in cervical cancer, which warrants further clinical translational investigations.

Automated summary

Preclinical studies have shown that vitamin D metabolites have anticancer effects by inducing apoptosis, inhibiting cell proliferation, and causing cell cycle arrest. In cervical cancer cells, there is an autocrine vitamin D metabolizing system (VDMS) that includes a vitamin D receptor, vitamin D catabolic enzyme (CYP24A1), and an activating enzyme (CYP27B1) for 25-hydroxycholecalciferol (25(OH)D3). This study demonstrates that physiological and supraphysiological doses of 25(OH)D3 inhibit cell growth and induce apoptosis in cervical cancer cells, potentially providing a promising therapeutic option.